Analysts Offer Predictions for ALLR FY2026 Earnings

Allarity Therapeutics, Inc. (NASDAQ:ALLR) – Equities research analysts at Ascendiant Capital Markets boosted their FY2026 earnings per share (EPS) estimates for Allarity Therapeutics in a research report issued to clients and investors on Saturday, June 6th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings per share of ($0.92) for the year, up from their previous forecast of ($0.96). Ascendiant Capital Markets currently has a “Buy” rating and a $10.25 target price on the stock. The consensus estimate for Allarity Therapeutics’ current full-year earnings is ($0.96) per share. Ascendiant Capital Markets also issued estimates for Allarity Therapeutics’ Q1 2027 earnings at ($0.25) EPS.

ALLR has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Monday, April 20th. Wall Street Zen upgraded Allarity Therapeutics to a “hold” rating in a research note on Saturday, May 30th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Allarity Therapeutics currently has a consensus rating of “Hold” and an average price target of $10.25.

Allarity Therapeutics Stock Performance

NASDAQ:ALLR opened at $1.49 on Thursday. The company has a market capitalization of $23.71 million, a price-to-earnings ratio of -2.07 and a beta of 0.52. Allarity Therapeutics has a one year low of $0.77 and a one year high of $2.35. The stock has a 50-day simple moving average of $1.43 and a 200 day simple moving average of $1.21.

Allarity Therapeutics (NASDAQ:ALLR) last announced its earnings results on Friday, May 15th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.05. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million.

Hedge Funds Weigh In On Allarity Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new stake in Allarity Therapeutics during the 4th quarter valued at $36,000. DRW Securities LLC acquired a new position in shares of Allarity Therapeutics during the fourth quarter valued at $133,000. Renaissance Technologies LLC increased its holdings in shares of Allarity Therapeutics by 274.1% during the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock valued at $267,000 after purchasing an additional 181,426 shares during the period. Capital Advisors Inc. OK bought a new stake in shares of Allarity Therapeutics during the fourth quarter valued at about $108,000. Finally, Citadel Advisors LLC bought a new stake in shares of Allarity Therapeutics during the third quarter valued at about $149,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.